ArticleFrontiers in cell and developmental biology2026
Effectiveness comparison of pembrolizumab versus other immune checkpoint inhibitors in neoadjuvant chemoimmunotherapy for esophageal squamous cell carcinoma.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Neoadjuvant chemoimmunotherapy (nICT) has emerged as a promising strategy for esophageal squamous cell carcinoma (ESCC). However, the efficacy and safety comparison of imported and domestic immune drugs remain unclear. This study aimed to compare short- and long-term efficacy between domestic and imported immunotherapeutic agents. Method: A total of 128 ESCC patients were retrospectively analyzed. Domestic immune drugs included sintilimab, tislelizumab, camrelizumab, and toripalimab, while the imported drug was pembrolizumab. Propensity score matching (PSM) was applied to balance baseline characteristics. Cox analysis, Kaplan-Meier survival and landmark analysis were used for survival analysis. Study outcomes included recurrence-free survival (RFS), locoregional recurrence-free survival (L-RFS), distant metastasis-free survival (D-MFS), pathological response, and postoperative complications. Result: 97 patients received domestic drugs and 31 received imported drugs. No significant differences were observed in RFS (p = 0.351), L-RFS (p = 0.075) and D-MFS (p = 0.772) before PSM. After PSM, survival outcomes remained comparable. 12th-month landmark analysis also showed no significant differences between two categories. Although imported drug was associated with a higher MPR rate before matching (p = 0.005), this difference was not significant after PSM (p = 0.128). Complication rates were similar except for fewer pleural effusions (p = 0.026) and more electrolyte disturbances (p = 0.030) in the imported group after PSM. Conclusion: Domestic and imported immune drugs demonstrated comparable long-term survival and safety in ESCC patients receiving nICT. Although imported agents may offer a modest advantage in pathological response, both categories remain effective options for clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.